Integrated Diagnostics partner to improve protein-based LC/MS assays Agilent Technology Inc.

Related StoriesUnderstanding how schizophrenia affects workings of the brainNew Global International and Energy Sustainability Group agree to manufacture, distribute MoringaUP Proteins BarsProtein sensor for proprioception found Agilent and Integrated Diagnostics share the vision of harnessing the power of an integrative systems biology approach to solving a few of mankind’s most vexing health challenges, said Gustavo Salem, vice president and general manager of the Biological Systems Division at Agilent. It is rather exciting to be at the forefront of helping technology migrate from the research laboratory to the clinic, in this full case developing next-generation workflows to boost protein-based LC/MS assays.Braunwald stated. Heart disease is the single leading reason behind death in the usa. More than 13 million adults have coronary heart disease, placing them at improved risk for heart attack, sudden death, angina, heart failure, and stroke. Most individuals with cardiovascular system disease, including coronary attack survivors, however, do not have heart failure or ventricular dysfunction. PEACE was designed to test whether ACE inhibitors offer benefits to this band of heart disease patients with fairly good heart function. The PEACE trial involved nearly 8300 participants who didn’t have heart failure, and who had normal or near regular left ventricular function, as evidenced by remaining ventricular ejection fraction in excess of 40 %. The common age of participants when the trial was started by them was 64 years.